Financial Comparison: Turnstone Biologics (TSBX) vs. Its Competitors

Turnstone Biologics (NASDAQ:TSBX) is one of 268 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Turnstone Biologics to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Turnstone Biologics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Turnstone Biologics	N/A	-174.96%	-72.80%
Turnstone Biologics Competitors	-5,349.89%	-220.52%	-47.61%

Analyst Ratings

This is a summary of current ratings and price targets for Turnstone Biologics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turnstone Biologics	0	2	2	0	2.50
Turnstone Biologics Competitors	1462	4471	11342	204	2.59

Turnstone Biologics currently has a consensus price target of $19.00, indicating a potential upside of 598.53%. As a group, “Biological products, except diagnostic” companies have a potential upside of 55.38%. Given Turnstone Biologics’ higher possible upside, equities research analysts clearly believe Turnstone Biologics is more favorable than its peers.

Valuation and Earnings

This table compares Turnstone Biologics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Turnstone Biologics	$19.31 million	-$55.20 million	-0.27
Turnstone Biologics Competitors	$574.98 million	-$36.37 million	-26.92

Turnstone Biologics’ peers have higher revenue and earnings than Turnstone Biologics. Turnstone Biologics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.